echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Fuhong Hanlin, a subsidiary of Fosun Pharmaceutical, obtained the first clinical approval for monoclonal antibody drugs

    Fuhong Hanlin, a subsidiary of Fosun Pharmaceutical, obtained the first clinical approval for monoclonal antibody drugs

    • Last Update: 2020-04-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On April 2, Fosun Pharmaceutical holding company Shanghai Fuhong Hanlin Biotechnology Co., Ltd

    (hereinafter referred to as "Fuhong Hanlin") formally received the approval document for clinical trial of recombinant human mouse chimeric anti-CD20 monoclonal antibody injection issued by the State Food and drug administration

    As the macromolecular R & D platform of Fosun Pharmaceutical, for more than four years, Fosun Hanlin has been adhering to the R & D concept of international standards, quality and efficiency priority, and implementing the R & D strategy of biological macromolecules

    This approval is the first clinical approval of Fuhong Hanlin since its establishment, and also the first clinical approval of monoclonal antibody drugs obtained by Fosun Pharmaceutical holding member enterprises

    It is reported that Fuhong Hanlin has so far completed the clinical registration application for 4 monoclonal antibody varieties and 5 indications

    Fosun Pharmaceutical always takes independent innovation as the source power of enterprise development

    The company continues to pay attention to innovation and R & D, improve the drug R & D innovation system of "combination of imitation and innovation"

    By continuously increasing investment in the "4 + 1" R & D platform, Fosun Pharmaceutical fully supports R & D innovation and promotes the listing of new products

    As a national enterprise technology center, the company has established an efficient international R & D team in Shanghai, Chongqing and the United States.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.